arrow_back Back to App

Support for Research on Valley Fever Treatment

This act aims to accelerate the development of drugs and prevention methods for coccidioidomycosis, also known as Valley Fever. By doing so, pharmaceutical companies can bring new therapies to market faster, potentially improving access to treatment and public health, especially in regions affected by this disease.
Key points
Coccidioidomycosis (Valley Fever) has been added to the list of tropical diseases eligible for the FDA's priority review voucher program.
Companies developing drugs for this disease may receive faster approval, encouraging investment in research and development.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_6227
Sponsor: Rep. Schweikert, David [R-AZ-1]
Process start date: 2023-11-03
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_6227.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-11-03.

What are the main provisions?

Key points include:

  • Coccidioidomycosis (Valley Fever) has been added to the list of tropical diseases eligible for the FDA's priority review voucher program.
  • Companies developing drugs for this disease may receive faster approval, encouraging investment in research and development.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Schweikert, David [R-AZ-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health